New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 250mg - capsule - 250 mg - active: zidovudine 250mg excipient: gelatin ink magnesium stearate maize starch microcrystalline cellulose sodium starch glycolate - retrovir oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; glycerol; maltitol solution; purified water; sodium benzoate; saccharin sodium; flavour - (1) treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex). (2) treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. new indications as at 11 may 1994: retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established . combination therapy in advanced hiv infection: the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy f

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; maize starch; microcrystalline cellulose; sodium starch glycollate; magnesium stearate; indigo carmine; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide - retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established. . combination therapy in advanced hiv infection. the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy for adult patients with hiv infection who fulfil the approved indications. new indications approved 7th february 1997: retrovir (zidovudine) is indicated for the treatment of hiv infection, alone and in combination with other antiretroviral therapies. the

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 100 mg - capsule - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; maize starch; magnesium stearate; titanium dioxide; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; strong ammonia solution; ethanol absolute; iron oxide black; ethanol; shellac; sulfuric acid; potassium hydroxide - retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established. . combination therapy in advanced hiv infection. the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy for adult patients with hiv infection who fulfil the approved indications. new indications approved 7th february 1997: retrovir (zidovudine) is indicated for the treatment of hiv infection, alone and in combination with other antiretroviral therapies. the

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - solution for infusion - zidovudine 200 mg / 20 ml - zidovudine - zidovudine - retrovir iv for infusion is indicated for the short term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immuno deficiency syndrome (aids) or aids who are unable to take retrovir oral formulations.retrovir chemoprophylaxis, is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants. retrovir i.v. should only be used when oral treatment is not possible (except during labour and delivery).

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 10 mg/ml - oral solution - 10 mg/ml - active: zidovudine 10 mg/ml excipient: citric acid monohydrate glycerol hydrogenated glucose syrup purified water saccharin sodium sodium benzoate strawberry flavour phl-134189 white sugar flavour da13780 - retrovir oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 100mg - capsule - 100 mg - active: zidovudine 100mg excipient: gelatin ink magnesium stearate maize starch microcrystalline cellulose sodium starch glycolate - retrovir oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 10 mg/ml - solution for injection - 200mg/20ml - active: zidovudine 10 mg/ml excipient: hydrochloric acid sodium hydroxide water for injection - retrovir iv for infusion is indicated for the short-term management of serious manifestations of human immunodeficiency virus (hiv) infection in patients with acquired immune deficiency syndrome (aids), who are unable to take retrovir oral formulations.

United States - English - NLM (National Library of Medicine)

janssen products, lp - bedaquiline fumarate (unii: p04qx2c1a5) (bedaquiline - unii:78846i289y) - bedaquiline 100 mg - sirturo is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (mdr-tb). reserve sirturo for use when an effective treatment regimen cannot otherwise be provided. this indication is approved under accelerated approval based on time to sputum culture conversion [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. limitations of use: - do not use sirturo for the treatment of: latent infection due to mycobacterium tuberculosis drug-sensitive tuberculosis extra-pulmonary tuberculosis infections caused by non-tuberculous mycobacteria - latent infection due to mycobacterium tuberculosis - drug-sensitive tuberculosis - extra-pulmonary tuberculosis - infections caused by non-tuberculous myco

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - zidovudine - capsules - zidovudine 250 mg - zidovudine - retrovir oral formulations are indicated in anti-retroviral combination therapy for human immunodeficiency virus (hiv) infected adults and children.retrovir chemoprophylaxis is indicated for use in hiv-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal hiv transmission and for primary prophylaxis of hiv infection in newborn infants.